Annual Total Liabilities
$8.20 M
+$581.00 K+7.63%
December 31, 2023
Summary
- As of February 7, 2025, CYCC annual total liabilities is $8.20 million, with the most recent change of +$581.00 thousand (+7.63%) on December 31, 2023.
- During the last 3 years, CYCC annual total liabilities has risen by +$4.66 million (+131.39%).
- CYCC annual total liabilities is now -90.16% below its all-time high of $83.34 million, reached on December 31, 2003.
Performance
CYCC Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$6.35 M
-$840.00 K-11.68%
September 30, 2024
Summary
- As of February 7, 2025, CYCC quarterly total liabilities is $6.35 million, with the most recent change of -$840.00 thousand (-11.68%) on September 30, 2024.
- Over the past year, CYCC quarterly total liabilities has dropped by -$1.85 million (-22.53%).
- CYCC quarterly total liabilities is now -92.38% below its all-time high of $83.34 million, reached on December 31, 2003.
Performance
CYCC Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
CYCC Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.6% | -22.5% |
| 3 y3 years | +131.4% | -14.4% |
| 5 y5 years | +80.1% | -14.4% |
CYCC Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.6% | -24.1% | +42.4% |
| 5 y | 5-year | at high | +131.4% | -24.1% | +144.9% |
| alltime | all time | -90.2% | +131.4% | -92.4% | +144.9% |
Cyclacel Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.35 M(-11.7%) |
| Jun 2024 | - | $7.19 M(-14.1%) |
| Mar 2024 | - | $8.37 M(+2.1%) |
| Dec 2023 | $8.20 M(+7.6%) | $8.20 M(-0.0%) |
| Sep 2023 | - | $8.20 M(+20.4%) |
| Jun 2023 | - | $6.81 M(-8.2%) |
| Mar 2023 | - | $7.42 M(-2.6%) |
| Dec 2022 | $7.62 M(+39.9%) | $7.62 M(+70.8%) |
| Sep 2022 | - | $4.46 M(-13.2%) |
| Jun 2022 | - | $5.14 M(-17.4%) |
| Mar 2022 | - | $6.22 M(+14.3%) |
| Dec 2021 | $5.44 M(+53.6%) | $5.44 M(+49.7%) |
| Sep 2021 | - | $3.63 M(+16.6%) |
| Jun 2021 | - | $3.12 M(-17.3%) |
| Mar 2021 | - | $3.77 M(+6.4%) |
| Dec 2020 | $3.54 M(-1.9%) | $3.54 M(+27.7%) |
| Sep 2020 | - | $2.77 M(+7.0%) |
| Jun 2020 | - | $2.59 M(-0.1%) |
| Mar 2020 | - | $2.60 M(-28.1%) |
| Dec 2019 | $3.61 M(-20.7%) | $3.61 M(+12.0%) |
| Sep 2019 | - | $3.23 M(-13.6%) |
| Jun 2019 | - | $3.73 M(-5.6%) |
| Mar 2019 | - | $3.96 M(-13.1%) |
| Dec 2018 | $4.55 M(+7.4%) | $4.55 M(+10.8%) |
| Sep 2018 | - | $4.11 M(+0.1%) |
| Jun 2018 | - | $4.11 M(-6.3%) |
| Mar 2018 | - | $4.38 M(+3.4%) |
| Dec 2017 | $4.24 M(-21.4%) | $4.24 M(-3.6%) |
| Sep 2017 | - | $4.39 M(-1.2%) |
| Jun 2017 | - | $4.45 M(+4.5%) |
| Mar 2017 | - | $4.25 M(-21.0%) |
| Dec 2016 | $5.39 M(-9.1%) | $5.39 M(-5.6%) |
| Sep 2016 | - | $5.71 M(-0.1%) |
| Jun 2016 | - | $5.71 M(+2.8%) |
| Mar 2016 | - | $5.56 M(-6.2%) |
| Dec 2015 | $5.93 M(-23.0%) | $5.93 M(+8.8%) |
| Sep 2015 | - | $5.45 M(-18.5%) |
| Jun 2015 | - | $6.69 M(-19.7%) |
| Mar 2015 | - | $8.33 M(+8.2%) |
| Dec 2014 | $7.70 M(+2.7%) | $7.70 M(+10.2%) |
| Sep 2014 | - | $6.99 M(-12.9%) |
| Jun 2014 | - | $8.02 M(-9.0%) |
| Mar 2014 | - | $8.81 M(+17.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $7.50 M(-19.7%) | $7.50 M(-16.5%) |
| Sep 2013 | - | $8.98 M(+36.5%) |
| Jun 2013 | - | $6.58 M(-9.3%) |
| Mar 2013 | - | $7.25 M(-22.3%) |
| Dec 2012 | $9.34 M(+43.7%) | $9.34 M(+27.9%) |
| Sep 2012 | - | $7.30 M(+8.2%) |
| Jun 2012 | - | $6.75 M(-0.8%) |
| Mar 2012 | - | $6.80 M(+4.7%) |
| Dec 2011 | $6.50 M(-0.6%) | $6.50 M(+9.5%) |
| Sep 2011 | - | $5.93 M(-1.7%) |
| Jun 2011 | - | $6.04 M(-11.3%) |
| Mar 2011 | - | $6.81 M(+4.3%) |
| Dec 2010 | $6.54 M(-24.0%) | $6.54 M(-18.0%) |
| Sep 2010 | - | $7.96 M(-2.3%) |
| Jun 2010 | - | $8.15 M(-14.3%) |
| Mar 2010 | - | $9.51 M(+10.7%) |
| Dec 2009 | $8.59 M(-16.7%) | $8.59 M(-10.4%) |
| Sep 2009 | - | $9.60 M(-14.4%) |
| Jun 2009 | - | $11.21 M(+12.5%) |
| Mar 2009 | - | $9.97 M(-3.4%) |
| Dec 2008 | $10.31 M(-42.5%) | $10.31 M(-13.0%) |
| Sep 2008 | - | $11.85 M(-14.2%) |
| Jun 2008 | - | $13.81 M(-2.6%) |
| Mar 2008 | - | $14.18 M(-20.9%) |
| Dec 2007 | $17.94 M(+91.8%) | $17.94 M(+51.2%) |
| Sep 2007 | - | $11.87 M(-6.6%) |
| Jun 2007 | - | $12.71 M(-9.9%) |
| Mar 2007 | - | $14.10 M(+50.7%) |
| Dec 2006 | $9.36 M(-37.4%) | $9.36 M(+14.3%) |
| Sep 2006 | - | $8.18 M(-2.8%) |
| Jun 2006 | - | $8.42 M(-33.9%) |
| Mar 2006 | - | $12.74 M(-14.8%) |
| Dec 2005 | $14.95 M(+30.2%) | $14.95 M(+24.6%) |
| Sep 2005 | - | $12.00 M(+19.9%) |
| Jun 2005 | - | $10.01 M(-12.4%) |
| Mar 2005 | - | $11.43 M(-0.5%) |
| Dec 2004 | $11.48 M(-86.2%) | $11.48 M(+41.4%) |
| Sep 2004 | - | $8.12 M(+20.1%) |
| Jun 2004 | - | $6.76 M(+5.7%) |
| Mar 2004 | - | $6.40 M(-92.3%) |
| Dec 2003 | $83.34 M(+19.6%) | $83.34 M |
| Dec 2002 | $69.66 M(+14.2%) | - |
| Dec 2001 | $60.99 M(+13.2%) | - |
| Dec 2000 | $53.86 M | - |
FAQ
- What is Cyclacel Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual total liabilities year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly total liabilities year-on-year change?
What is Cyclacel Pharmaceuticals annual total liabilities?
The current annual total liabilities of CYCC is $8.20 M
What is the all time high annual total liabilities for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual total liabilities is $83.34 M
What is Cyclacel Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, CYCC annual total liabilities has changed by +$581.00 K (+7.63%)
What is Cyclacel Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of CYCC is $6.35 M
What is the all time high quarterly total liabilities for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly total liabilities is $83.34 M
What is Cyclacel Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, CYCC quarterly total liabilities has changed by -$1.85 M (-22.53%)